Canine prostatic adenocarcinoma is a rare but highly aggressive cancer that is typically diagnosed at an advanced stage, due to the lack of effective screening methods and poor recognition of early lesions. Cancer stem cells are known to drive tumour progression and treatment resistance in human prostate cancer, but their role in naturally occurring canine disease remains poorly defined. A deeper understanding of the biology of canine prostatic adenocarcinoma is therefore essential to improve prognosis and to develop relevant comparative models. We established and comprehensively characterised two novel canine prostatic adenocarcinoma cell lines, Kodiak and Bobby, with detailed comparison to their tumours of origin and, for Kodiak, xenografts generated in immunodeficient mice. Both lines displayed variable epithelial morphology influenced by culture conditions, and Kodiak xenografts recapitulated key histopathological patterns of the primary tumour. Expression of the luminal epithelial marker CK8/18 and the basal marker CK14 was largely retained across tumour, cell line, and xenograft, whereas the basal markers CK5 and p63, and the urothelial marker UPIII, were diminished or lost during in vitro culture. Evaluation of cancer stem cell-associated markers showed consistent expression of CD44, Nanog, Oct3/4, and Sox2 in the original tumours and cell lines, while CD133, Nestin, and Trop2 were present in the tumours but absent in vitro, indicating selective loss of specific stem-like populations. Media-dependent plasticity was evident in the Bobby line. These models retain key epithelial and stemness features and provide robust platforms for translational prostate cancer research in dogs and humans.
BackgroundPremature atherosclerosis and cardiovascular morbidity are known in adults with Systemic Lupus Erythematosus (SLE); however, there is paucity of data in Indian children with lupus nephritis (LN), who may be at higher cardiovascular risk due to ethnic differences.MethodsThis cross-sectional study was conducted at the pediatric nephrology clinic of a referral hospital in south India. Forty children with LN >1 year disease duration and 40 healthy-controls were enrolled. Brachial artery flow-mediated dilatation (FMD), carotid intima medial thickness (cIMT), and echocardiography for left ventricular (LV) mass, LV systolic and diastolic function, and global-longitudinal-strain (GLS) were done.ResultsMean age at SLE and LN diagnosis were 10.07 years and 10.68 years respectively, with median LN disease duration of 3.2 years. Class 3 and Class 4 LN accounted for 67.5% of the cases. Overall, 6 (15%) LN cases had concentric LVH, while 4 (10%) had biplane ejection fraction≤ 55%. Mean resting brachial artery diameter was lower in cases (n = 40) than age and sex-matched healthy-controls (n = 40) (2.7 mm vs 2.9 mm, p 0.010), although median proportionate change in FMD was comparable [13.84% (8.17%, 20.31%) versus 14.49% (12.21%, 17.24%); p 0.413]. However, proportionate change in FMD <10% was more prevalent in cases vs controls (35% vs 10%, p 0.007). Cardiac assessments showed higher A-wave velocity (69.03 ± 18.0 cm/s vs 58.64 ± 11.93 cm/s, p 0.003) and lower E/A ratio (1.56 ± 0.49 vs 1.80 ± 0.44, p 0.030) in cases vs controls; with elevated medial a' velocity (8.98 ± 2.01 vs 7.94 ± 2.12 cm/s, p 0.030). Pulmonary venous Doppler revealed shorter atrial reversal duration (85.82 ± 18.7 vs 102.25 ± 17.8 ms, p 0.001) and reduced A-wave duration (118.08 ± 19.73 vs 128.67 ± 20.27 ms, p 0.023) among cases. GLS was lower in cases (-21.59 ± 3.06% vs -22.95 ± 2.38%, p 0.030), and median LV mass was higher in cases vs controls (92.7 g vs 72.1 g, p < .001).ConclusionSouth Indian children with LN of >1 year disease duration demonstrate significant cardiovascular comorbidities, including evidence of endothelial dysfunction, as well as LV systolic and diastolic dysfunction.
暂无摘要（点击查看详情）
Ankyloglossia may cause breastfeeding difficulties, potentially leading to early cessation of exclusive breastfeeding (EBF). However, increases in rates of frenotomy have not resulted in increases in EBF rates, and, in some regions, ankyloglossia is not regarded as a major barrier to successful breastfeeding. We sought to elucidate the contribution of untreated ankyloglossia to early cessation of EBF. We conducted a sequential explanatory mixed-methods study at an urban tertiary care hospital for women and children in Hyderabad, India. We evaluated for ankyloglossia and breastfeeding difficulties in mother-infant dyads recruited within 48 hours after birth. Primary outcomes of EBF and infant weight gain were compared between infants with (tongue-tie [TT]) or without (No-TT) ankyloglossia. Semistructured interviews were conducted to identify reasons contributing to early cessation. A total of 476 dyads were recruited over 3 months. There was no significant difference in rates of EBF at 6 months (No-TT 81.4% vs TT 78.6%; P = .6) or infant weight gain velocity from 0 to 3 months (No-TT 26.3 g/d vs TT 26 g/d; P = .86) or from 3 to 6 months (19.3 g/d vs 20.4 g/d; P = .49). Maternal concern for inadequate supply was associated with lower EBF odds at 6 months (odds ratio 0.22; P = .003). Mothers with early cessation in either group rarely reported issues with infant breastfeeding skill or nipple pain. Although ankyloglossia may affect breastfeeding experiences, ankyloglossia alone does not appear to affect breastfeeding maintenance or infant weight gain. Improving breastfeeding outcomes should include multidisciplinary management to focus on all potential causes and not only ankyloglossia.
Current spatial T cell receptor (TCR) profiling approaches lack the resolution needed to link clonal identity, transcriptional state, and spatial positioning of individual T cells in the tumor microenvironment. Here, we introduce a spatial TCR profiling strategy that resolves individual T cell clones together with their transcriptional states at single-cell resolution and applied the method to human head and neck squamous cell carcinoma. Presumed tumor-specific T cells were broadly dispersed throughout the tumor microenvironment, and cells of the same clone occupied distinct transcriptional states in different locations: Immune-rich regions contained more plastic or progenitor cells, whereas tumor-dense regions were enriched for exhausted states. Patients exhibited notably different spatial architectures of antitumor T cell responses, revealing variation that was not captured by high-resolution, spatially agnostic methods such as spectral flow cytometry and single-cell RNA sequencing. These results provide a blueprint for dissecting antigen-specific T cell states in human tumors and reveal how T cell states are spatially coordinated with local cues across the tumor microenvironment.
Nasal airway obstruction (NAO) is prevalent with substantial health and quality of life burdens. Nasal valve collapse (NVC) is one structural cause of NAO. Temperature-controlled radiofrequency (TCRF) nasal valve remodeling offers an alternative to invasive surgery. Clinical efficacy is established, but the impacts of TCRF on healthcare resource utilization (HRU) and cost in real-world settings remain underexplored. Two cohorts with NAO were defined from a large general NAO population: the TCRF cohort with an isolated TCRF (index) procedure and a propensity-matched medically managed (MM) cohort without nasal procedures. HRU and costs were evaluated within a 24-month pre-/post-index period for both. A total of 10,206 TCRF and 50,766 MM patients were analyzed. Significant post-index reductions were observed for TCRF across all-cause Evaluation & Management (E&M) visits, ENT-related procedures, and sleep-related claim categories. A large reduction in mean daily post-index costs was seen for the TCRF cohort: $68.07 pre-index to $38.75 post-index (-43.1%). Mean daily costs went up in the MM cohort from $42.08 pre-index to $63.26 post-index (+50.4%), resulting in total cost savings of $21,418.26 for the TCRF cohort and a total cost increase of $15,471.99 in the MM cohort in the 24-month post-index period. TCRF cost reductions were driven by reductions in NAO-related HRU. In this large, real-world analysis, TCRF treatment for NVC-related NAO demonstrated substantial reductions in HRU and total costs of care, demonstrating sustained savings over 2 years relative to MM patients.
Dysphonia in patients with Parkinson's Disease (PD) negatively impacts quality of life. Treatment options are evolving and include both invasive and non-invasive interventions. The present study aims to assess current therapies and their effectiveness through a scoping review of the literature. PubMed, Ovid, and Embase. Three databases were searched for articles through 2023 pertaining to treatment of PD-related dysphonia in accordance with PRISMA guidelines. Included studies were reviewed to extract demographic information, treatment techniques, and outcomes. Of 277 studies reviewed, 49 publications met inclusion criteria with a total of 1388 patients. Treatments were categorized into groups: voice therapy, pharmacologic intervention, deep brain stimulation (DBS), vocal fold augmentation, neurosurgical intervention, and dietary modification. Measures reported to assess outcomes were heterogenous across studies. Voice therapy had the highest number of studies with statistically significant results, totaling 18 studies. Other treatments, including DBS, demonstrated improvement in systemic symptoms with worsening of voice symptoms. The literature of current therapeutic options for PD patients with dysphonia is heterogenous; however, voice therapy remains standard of care. Further studies should emphasize standardization of voice metrics to permit head-to-head comparisons across treatment modalities. There is also an opportunity to leverage combining therapies for PD patients, but optimization of such regimens requires further investigation.
To discuss the effect of round window drill-out for otosclerosis cases with radiographic evidence of round window obliteration. Four adult patients (5 ears) were included with audiometric findings of a mixed hearing loss and radiographic evidence of otosclerosis causing round window obliteration. Round window obliterative disease was addressed with a formal round window drill-out (RWD) by opening the lumen of the basal turn of the cochlea with a micro drill. The opening was then reconstructed with fascia to recreate a 2-window system. Feasibility, Δ pure-tone air conduction thresholds, and Δ pure-tone average air-bone gap (PTA-ABG). Three (60%) ears underwent primary or revision stapedectomy with RWD, 1 (20%) ear underwent delayed RWD years after stapedectomy, and 1 (20%) ear underwent RWD without stapedectomy. Median preoperative PTA-ABG was 31.3 dB. One patient (2 ears) had significant benefit with PTA-ABG improvements of 45 dB (left) and 30 dB (right). Two patients (2 ears) had a small improvement in PTA-ABG (2.5 dB, 1.3 dB), whereas 1 patient (1 ear) had worsening in PTA-ABG (2.5 dB). Patients suffering from severe mixed hearing loss due to advanced otosclerosis may benefit from formal RWD to facilitate hearing aid use as an alternative to cochlear implantation.
We report positron scattering cross sections of fluorine and fluorine-containing molecules across an energy range from 1 to 5000 eV. Targets considered in the present study are F, F2, HF, CF4, C2F6, C6F6, CHF3, C2H3F3, and C2H2F2. Elastic, inelastic, total, and positronium formation cross sections were calculated using the optical potential approach, and the ionisation cross sections are estimated employing the complex scattering potential-ionisation contribution method. The computed results are in satisfactory agreement with available theoretical data. Comparison with experiments shows excellent agreement in the high-energy range; however, discrepancies are observed at lower energies, attributed to deficiencies in the polarisation potential model used and, in part, to the difficulty in resolving forward-angle scattering effects in experimental measurements. Positron interactions with these molecules are important in plasma, astrophysics, and radiation physics, where ionisation, energy losses, and the formation and destruction of positronium are significant. The positron scattering cross-sections are primary inputs for modelling in astrophysics, materials science, and medical imaging, such as positron emission tomography.
In children with Chiari type I malformation and syringomyelia, neurosurgical posterior fossa decompression (PFD) provides clinical improvement, but whether duraplasty (incising the dura and placing a dural graft) improves outcomes is unclear. We conducted a multicenter, cluster-randomized, controlled trial of PFD with duraplasty (PFD-D) as compared with PFD alone. Persons 21 years of age or younger with cerebellar tonsillar ectopia of at least 5 mm and a maximum syrinx diameter of 3.0 to 9.9 mm were enrolled at 38 centers. Centers were cluster-randomized: all the participants within each center underwent the same intervention. The primary outcome was surgical complications within 6 months. Secondary outcomes were clinical improvement, syrinx reduction, and repeat decompression at 10 to 24 months and the change in overall health-related quality of life at 6 to 24 months. A total of 162 participants were included in the trial, of whom 78 were assigned to undergo PFD-D and 84 to undergo PFD alone. The percentage of participants with complications within 6 months was 14% with PFD-D and 6% with PFD (adjusted odds ratio, 2.59; 95% confidence interval [CI], 0.86 to 7.84; P = 0.11). At 24 months, the percentage of participants with clinical improvement was 58% with PFD-D and 46% with PFD; the mean (±SD) syrinx reduction was 3.08±2.33 mm and 1.22±1.79 mm, respectively; and the percentage of participants with repeat decompression was 3% and 14%. Changes in health-related quality of life were similar in the two groups. The percentage of participants with surgical complications did not differ significantly between those who underwent PFD-D and and those who underwent PFD alone. Larger trials are needed to determine the relative benefits and risks of these two procedures. (Funded by the Patient-Centered Outcomes Research Institute and others; ClinicalTrials.gov number, NCT02669836.).
暂无摘要（点击查看详情）
Head and neck squamous cell carcinoma (HNSCC) is characterized by frequentTP53mutations, which include gain-of-function (GOF) variants that drive tumor progression and chemoresistance. While genomic evidence across multiple specimens ranging from oral pre-malignant lesions (OPL) through invasive and metastatic HNSCC indicates that TP53 loss or mutation occurs relatively early in HNSCC carcinogenesis, it has been difficult to discern how mutation of this tumor suppressor drives further tumor cell evolution and influences the tumor microenvironment to drive tumor progression. To address this question, we generated an immortalized human oral keratinocyte (iHOK) cell line expressing wt TP53 as well as TP53 mutant forms to determine how mutations impact functional and genomic characteristics of HOKs that can in turn drive their evolution to neoplastic cells. We established a novel panel of iHOK cell lines harboring distinctTP53mutations, including the high-risk C238F variant. Key results revealed significant phenotypic and molecular divergence: high-risk lines exhibited enhanced invasiveness and chemoresistance compared to low-risk counterparts. Weighted gene co-expression network analysis (WGCNA) linked high-risk mutations to pro-metastatic pathways and stress-response signatures, with the C238F line uniquely enriched for p53-related GOF mechanisms. Conversely, low-risk lines remained chemosensitive. These findings underscore the clinical relevance of mutation-specific iHOK models in determining the transcriptomic events that drive invasiveness and drug resistance and identify ways to intercept these phenotypes. By mirroring theTP53diversity observed in patient tumors, this cell line panel bridges a critical gap in head and neck carcinogenesis research, enabling mechanistic dissection of GOF phenotypes and preclinical evaluation of therapies in an array of TP53mutant cell models. Its significance lies in providing a validated, annotated resource that accelerates drug discovery and clarifies the role ofTP53mutational subtypes in HNSCC development and progression, offering a framework for future translational studies in genetically complex malignancies.
The incidence of right-sided infective endocarditis is increasing with injection drug use, indwelling lines, and device implantation. Although contemporary guidelines emphasize early referral to heart valve centres and multidisciplinary endocarditis teams, many patients who meet surgical criteria are ineligible because of prohibitive risk, clinical instability, or social complexity. Percutaneous mechanical aspiration (PMA) with the AngioVac (AngioDynamics, Latham, NY) system has emerged as a minimally invasive option to debulk infected masses, expedite bacteremia clearance, and mitigate septic embolization, particularly for large tricuspid vegetations and device-related infection; highly selected left-sided infective endocarditis cases have also been reported. AngioVac couples a large-bore aspiration cannula to a veno-venous extracorporeal circuit with continuous transesophageal echocardiography; neuroprotection is routine for left-sided targets. Across heterogeneous right-sided infective endocarditis populations, technical success approximates 85%-90%. Comparative analyses vs tricuspid surgery show broadly similar early and 1-year mortality, with shorter length of stay after PMA. Cost and length of stay signals also favour PMA in cohort studies. Adjunctive use during transvenous lead extraction facilitates the removal of bulky vegetations and might improve survival. For left-sided experience with cerebral protection, complications include embolization, bleeding and/or transfusion, vascular or intracardiac injury, and persistent and/or worsened tricuspid regurgitation; conversion to surgery is uncommon. PMA with the AngioVac might serve as a bridge to definitive therapy and expands options for otherwise inoperable patients. Evidence remains retrospective and short-term. Pragmatic, multicentre trials with core lab echocardiography, standardized success definitions, and patient-centred end points are needed to refine indications and inform guideline integration.
Patient and Public Involvement (PPI) is widely endorsed within UK clinical research as both an ethical expectation and a mechanism for enhancing research relevance and quality. However, questions remain regarding how involvement functions in practice across institutional settings. Most studies examine PPI from single stakeholder perspectives, limiting understanding of how involvement is experienced across research systems. The DANIELLE study was co-produced with an established cancer PPI group and aimed to triangulate perspectives from multiple actors to examine how PPI is valued, evidenced and sustained within clinical research governance. A qualitative multi-cohort design was used. Forty semi-structured interviews were conducted with purposively sampled participants, including lay PPI contributors, clinical trial sponsor staff, professional PPI leads and Research Ethics Committee members. Participants were recruited through established PPI networks, NHS research governance contacts and professional research channels. Data were analysed using reflexive thematic analysis, with cross-cohort triangulation employed to identify shared structural patterns. Reflexive and co-production principles informed study design and interpretation. Five interconnected themes were generated: (1) PPI as ethically essential but structurally fragile; (2) authenticity versus performative compliance; (3) evidentiary gaps and the invisibility of contributor labour; (4) timing of involvement as a marker of authenticity; and (5) reliance on individual goodwill rather than institutional infrastructure. Across cohorts, participants described strong ethical commitment to involvement alongside systemic weaknesses in how experiential contributions are documented, recognised and sustained. The findings suggest that persistent challenges in PPI reflect features of research system design rather than isolated failures of engagement. Strengthening involvement requires movement from rhetorical endorsement toward infrastructural integration, including improved approaches to evidencing influence and earlier positioning of contributors within research development pathways. By triangulating stakeholder perspectives through a co-produced inquiry, the study conceptualises PPI as a shared system-level knowledge practice rather than an optional enhancement to research delivery. Patient and Public Involvement (PPI) means including patients and members of the public in shaping health research. In the UK, PPI is considered an ethical expectation, but there is ongoing debate about how well it works in practice. This study explored how PPI is experienced across the clinical research system. We interviewed four groups involved in research: public contributors, NHS research staff, professional PPI leads, and Research Ethics Committee members. By comparing their perspectives, we examined how involvement is valued, recorded, and supported. All groups agreed that PPI is important and can improve research. However, participants described weaknesses in how involvement is protected within institutions. Public contributors often felt their work became invisible once studies entered formal approval systems. Professionals described a lack of clear ways to show how PPI changes research. Ethics committees reported difficulty checking whether involvement was meaningful or simply a requirement to complete. Participants also emphasised that early involvement leads to stronger research, while late consultation risks becoming a “tick-box” exercise. Across the system, meaningful PPI was often sustained by individual goodwill rather than strong institutional structures. The findings suggest that improving PPI requires system-level change. Better ways of documenting impact, involving contributors earlier, and recognising contributor labour are needed. PPI should be supported as a core part of research infrastructure, not an optional extra.
The management of nonobstructive azoospermia (NOA) is challenging. Even the most successful intervention for this condition, microsurgical testicular sperm extraction (microTESE) with in vitro fertilization (IVF)-intracytoplasmic sperm injection (ICSI), is not successful at least 40% of the time. Varicocele is present in 15% of young men, and varicocelectomy improves fertility outcomes in men with palpable varicoceles and abnormal semen analyses. Unfortunately, there are limited investigations into the effect of varicocelectomy in men with NOA. Uncontrolled cohort studies report the return of sperm to the ejaculate after treatment of the varicoceles in men with NOA. That finding should be viewed in the context that sperm are found in the subsequent semen analyses of men with NOA without any intervention. Limited controlled studies do report higher rates of sperm retrieval during microTESE in men with treated varicoceles compared with controls. The histopathology of testicular biopsies obtained during varicocelectomy correlates with the return of sperm to the semen and sperm retrieval rates during subsequent microTESE The evidence supporting varicocele treatment in men with NOA is very limited, and clinicians should make this fact clear when counseling patients with these conditions.
Immune checkpoint inhibitors (ICIs) have revolutionised cancer treatment through targeted disruption of the physiological pathways that maintain tissue tolerance, but which are co-opted by cancers to evade immunosurveillance. Thus, the resultant T-cell activity often causes immune-related adverse events including immune checkpoint inhibitor-induced inflammatory arthritis (ICI-IA). ICI-IA results in functional impairment that frequently persists, even after ICI discontinuation, with substantial quality-of-life impacts for cancer survivors.A high-quality body of evidence to guide ICI-IA management remains an unmet need. Pharmacological treatment may be prolonged, typically begins with non-specific immunosuppression, including systemic steroids, and is usually only rationalised to more targeted therapy in resistant cases. Moreover, retrospective data suggest the high dose glucocorticoids sometimes used in new-onset ICI-IA may be associated with worse cancer outcomes.Tumour necrosis factor (TNF) inhibition strategies are well established with excellent efficacy and safety profiles in 'spontaneous' inflammatory arthritides including rheumatoid and psoriatic arthritis. Mechanistic evidence from ex vivo and murine studies also supports the utility of anti-TNF therapy for steroid-refractory cases of ICI-IA. Although good clinical responses have been reported in this setting, the REACT trial (REmission induction of Arthritis caused by Cancer ImmunoTherapy) aims to provide randomised and robust clinical evidence for deploying targeted therapy earlier in ICI-IA management. It will test whether up-front anti-TNF therapy can more effectively and quickly control symptoms, reduce glucocorticoid exposure, prevent early ICI discontinuation and increase the frequency of drug-free ICI-IA remission. REACT is a prospective, multicentre, open-label, superiority, two-arm, randomised controlled clinical trial to guide initial therapy for patients with ICI-IA. The trial will compare the current standard of care (initial prednisolone; Arm A) with the anti-TNF drug, adalimumab without glucocorticoids (Arm B).The primary outcome is glucocorticoid-free arthritis remission rate at 24 weeks where remission is defined as: (i) No use of systemic or intra-articular glucocorticoids (except when used for adrenal insufficiency) within 4 weeks prior to assessment at 24 weeks; and (ii) absence of synovitis on clinical examination. The protocol was approved by East Midlands-Leicester South Research Ethics Committee on 31-Oct-2024 (Ref: 24/EM/0202). Participants are required to provide written informed consent. The results of this trial will be disseminated through national and international presentations and peer-reviewed publications. ISRCTN18217497.
Somatic mutation testing in solid tumours represents a rapidly advancing field which increases opportunities for access to molecularly targeted therapeutics and clinical trials. This systematic review determined whether socio-demographic inequalities affect utilisation of novel somatic mutation testing. Following PRISMA 2020 guidance, MEDLINE, EMBASE, Scopus, CINAHL, Web of Science, PubMed and PsycINFO were searched for peer-reviewed studies (January 2018-March 2025). Data was extracted reporting utilisation of novel somatic mutation testing panels, including Oncotype DX, for solid tumours by socio-demographic measures. A modified International Society for Pharmacoeconomics and Outcomes Research (ISPOR) checklist assessed study quality. Unadjusted odds ratios (ORs) and 95% confidence intervals (CIs) were calculated where needed and narrative synthesis undertaken. Data was stratified by receipt of Oncotype DX testing and next-generation sequencing (NGS) panels. The 27,749 citations screened identified 24 studies meeting the inclusion criteria. These reported on two modalities of testing (Oncotype DX and other NGS sequencing panels) across five cancers. Twenty-three studies were from US populations. These highlighted disparities in utility of testing across socio-demographic measures and particularly decreased utilisation with increased age, non-white ethnicity, lower socio-economic status, and non-private insurance. The mean study quality score by a modified ISPOR checklist was 8.3/10. These results provide a contemporary update on evidence of disparities in access to novel genomic testing. As an expanding field, this requires further investigation to prevent accentuations in inequitable implementation of precision oncology and differences in outcomes between different socio-demographic groups.
Albumin, a major carrier of perfluoroalkyl and polyfluoroalkyl substances (PFAS) in humans and animals, has been rarely explored for PFAS removal. In this study, bovine serum albumin (BSA) is transformed into an efficient, low-cost, and reusable adsorbent for PFAS removal. BSA is modified with amine-rich poly(ethylenimine) (PEI) to create a positively charged surface. The optimal PEI:BSA mass ratio was determined to be 0.75 based on a combination of adsorption performance and material properties. The resulting PB(0.75) achieves rapid equilibrium for nine model PFASs, with a pseudo-second order rate constant range from 0.6 to 15.7 g/(mg.min), depending on the specific PFAS. In addition to fast kinetics, PB(0.75) exhibits exceptionally high adsorption capacities for PFHpA, PFOA, PFNA, and PFOS, each exceeding 1000 mg/g. These values rank among the highest reported to date for these PFAS. Adsorption of shorter-chain and emerging PFASs such as PFBA, PFBS, GenX, and 6:2 FTS is comparatively lower but still moderately better than conventional activated carbons reported in the literature. The adsorption mechanism is thoroughly investigated by examining adsorption behaviors under different water matrixes, constructing modified linear solvation energy relationships, and characterizing PB(0.75) before and after adsorption. The adsorption process is governed by electrostatic attraction and hydrophobic interactions, with short-chain PFAS relying more on electrostatic interactions due to their higher hydrophilicity. Furthermore, exhausted PB(0.75) can be effectively desorbed and regenerated by using alkaline solutions. Our study highlights albumin-based adsorbents as a highly promising and sustainable solution for addressing PFAS contamination in aquatic environments.